SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms

Mosbech, H.; Canonica, Giorgio Walter; Backer, Vibeke; Blay, F. De; Klimek, Ludger; Broge, Louise; Ljørring, Christian

doi:10.1016/j.anai.2014.11.015

Cited by 81 publications

(68 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…86,87,108,109 Sublingual house dust mite (HDM) tablet immunotherapy for at least 1 year is recommended (Grade A) for the short-term treatment of perennial HDM AR in adults. [50][51][52][53][54][55] While higher doses and/or increased cumulative doses may be more effective, they may be associated with more side-effects [56][57][58] ; decisions on dose in AIT must be made balancing efficacy and sideeffects. 59 …”

Section: General Indications Key References Contextual Considerationsmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

594

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

Section: General Indications Key References Contextual Considerationsmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

594

705

View full text Add to dashboard Cite

show abstract

“…The clinical efficacy of the SQ HDM SLIT-tablet for HDMinduced AR has been evaluated in three randomized, double-blind, placebo-controlled trials [44][45][46], as outlined in Table 1. In addition to the listed trials based in Europe, the SQ HDM SLIT-tablet has been evaluated in one phase III trial in North America and two phase III trials in Japan.…”

Section: Phase II and Phase Iii Studiesmentioning

confidence: 99%

“…2006-001795-20), a large phase II trial investigating the efficacy and safety of the SQ HDM SLITtablet in adults and adolescents with HDM-induced respiratory allergic disease, impact on AR was evaluated by a combined rhinitis symptom and medication score (total combined rhinitis score, TCRS) [45]. The primary end point in this trial related to HDM-induced allergic asthma [47] and the trial population was selected based on mild to moderate HDM-induced allergic asthma as well as a medical history of HDM-induced AR.…”

Section: Phase II and Phase Iii Studiesmentioning

confidence: 99%

SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis

Klimek

Mosbech

Zieglmayer

et al. 2016

Expert Review of Clinical Immunology

Self Cite

View full text Add to dashboard Cite

House dust mite (HDM) allergy represents a highly prevalent inhalant allergy, and exposure to HDM allergens results in allergic rhinitis with persistent symptoms that may not be adequately controlled with available allergy pharmacotherapy. Allergy immunotherapy constitutes a complementary treatment option targeting the underlying immunological mechanisms of allergic disease and represents the only treatment with a potential for disease modification and long-term efficacy. As traditional allergy immunotherapy delivered by subcutaneous injection of specific HDM allergens involves a time-consuming treatment regimen and a risk of systemic adverse reactions, sublingually administered allergy immunotherapy (SLIT) has been investigated as a more convenient treatment option with similar levels of efficacy and an improved safety profile that allows for at-home daily administration. In this Drug Profile, we provide a review of the clinical data behind the SQ HDM SLIT-tablet, which was recently approved for the treatment of HDM-induced allergic rhinitis by regulatory authorities in Europe and Japan.ARTICLE HISTORY

show abstract

“…A similar scoring system can be used for ocular symptoms, including "eye itching", "ocular secretion" and "eye redness", to attain a total ocular symptom score that ranges from 0 to 9. Nasal symptoms and medication can be evaluated daily using a computer software-based documentation system, whereas quality of life can be assessed each year (229). VAS is generally recommended for subjective symptom evaluation by patients (1,228).…”

Section: Nasal Symptoms Sorementioning

confidence: 99%